Glenmark Commences Phase II Study of GBR 500 for Ulcerative Colitis

Glenmark Pharmaceuticals, a research-driven, integrated pharmaceutical company, has begun Phase II study for GBR 500, an antagonist of the VLA2 (alpha2-beta1) integrin, for ulcerative colitis.
Pharmaceutical Business Review